Predictors of difficulty when discontinuing postmenopausal hormone therapy

被引:75
作者
Grady, D
Ettinger, B
Tosteson, ANA
Pressman, A
Macer, JL
机构
[1] Univ Calif San Francisco, Dept Epidemiol & Biostat, Womens Hlth Clin Res Ctr, San Francisco, CA 94143 USA
[2] Kaiser Permanente Med Care Program, Div Res, Oakland, CA USA
[3] Dartmouth Coll Sch Med, Hanover, NH USA
关键词
D O I
10.1016/j.obstetgynecol.2003.09.025
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To describe the experiences of postmenopausal women who try to stop hormone therapy and to identify characteristics associated with inability to stop. METHODS: We conducted telephone interviews with 377 randomly selected female members of the Kaiser Foundation Health Plan, aged 50-69 years, who regularly used hormone therapy for at least 1 year before July 1, 2002 and had attempted to stop between July 2002 and March 2003. RESULTS: Of the 377 women, 280 (74%) successfully stopped and 97 (26%) resumed taking hormone therapy The major predictor of resuming hormone therapy use was the development of troublesome withdrawal symptoms (odds ratio 8.8; 95% confidence interval 4.9,16.0). Report of hysterectomy, hormone therapy prescribed by a nongynecologist, and perception of high risk of hip or spine fracture were independently associated with a higher likelihood of unsuccessful stopping. Women with a hysterectomy who had used hormone therapy for 10 or more years and who started hormone therapy mainly for reasons other than health promotion were more likely (P <.001) to be unsuccessful in quitting (44%) compared with those with one or two (25%) or none (9%) of these three characteristics. Most successful stoppers (71%) stopped hormone therapy abruptly, but 29% tapered off hormone therapy; there was no difference in the incidence of troublesome withdrawal symptoms or successful quitting between these two groups. CONCLUSION: Approximately one quarter of women who try to stop report that they are unable to discontinue postmenopausal hormone therapy, primarily because they develop troublesome withdrawal symptoms. Effective approaches to reducing hormone therapy withdrawal symptoms should be a priority for future research.
引用
收藏
页码:1233 / 1239
页数:7
相关论文
共 12 条
[1]  
*AM COLL OBST GYN, 2003, QUEST ANSW HORM THER
[2]  
COLATA G, 2002, NY TIMES 0901, P1
[3]   Effect of the women's health initiative on women's decisions to discontinue postmenopausal hormone therapy [J].
Ettinger, B ;
Grady, D ;
Tosteson, ANA ;
Pressman, A ;
Macer, JL .
OBSTETRICS AND GYNECOLOGY, 2003, 102 (06) :1225-1232
[4]   Continuation of postmenopausal hormone replacement therapy: Comparison of cyclic versus continuous combined schedules [J].
Ettinger, B ;
Li, DK ;
Klein, R .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 1996, 3 (04) :185-189
[5]   BEHAVIORAL TREATMENT OF MENOPAUSAL HOT FLUSHES - EVALUATION BY AMBULATORY MONITORING [J].
FREEDMAN, RR ;
WOODWARD, S .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 167 (02) :436-439
[6]   Noncardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II) [J].
Hulley, S ;
Furberg, C ;
Barrett-Connor, E ;
Cauley, J ;
Grady, D ;
Haskell, W ;
Knopp, R ;
Lowery, M ;
Satterfield, S ;
Schrott, H ;
Vittinghoff, E ;
Hunninghake, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (01) :58-66
[7]  
*N AM MEN SOC, 2003, AM REP NAMS ADV PAN, V10, P6
[8]  
*NAT COMM QUAL ASS, MAN MEN INF CHOIC
[9]   Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial [J].
Rossouw, JE ;
Anderson, GL ;
Prentice, RL ;
LaCroix, AZ ;
Kooperberg, C ;
Stefanick, ML ;
Jackson, RD ;
Beresford, SAA ;
Howard, BV ;
Johnson, KC ;
Kotchen, JM ;
Ockene, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (03) :321-333
[10]   Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women - The Women's Health Initiative Memory Study: A randomized controlled trial [J].
Shumaker, SA ;
Legault, C ;
Rapp, SR ;
Thal, L ;
Wallace, RB ;
Ockene, JK ;
Hendrix, SL ;
Jones, BN ;
Assaf, AR ;
Jackson, RD ;
Kotchen, JM ;
Wassertheil-Smoller, S ;
Wactawski-Wende, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (20) :2651-2662